Skip to main content
. 2017 Feb 23;8(19):31478–31493. doi: 10.18632/oncotarget.15649

Figure 4. Co-exposure of DLBCL to volasertib and belinostat leads to induction DNA damage, downregulates c-Myc and knocking down of c-Myc potentiates the lethality of volasertib.

Figure 4

A. SU-DHL4, OCI-Ly18 and U2932 cells were treated with volasertib (10-25nM) alone or with belinostat (200-400 nmol/L) for 24 hr after which cells were lysed and proteins extracted. Expression of the indicated proteins was determined by Western blotting using the indicated antibodies. Each lane was loaded with 25 μg of protein; blots were stripped and re-probed with tubulin to ensure equivalent loading and transfer. Results are representative of three replicate experiments. Numbers under the blots correspond to densitometric values normalized to controls arbitrarily set to 1.0. B. SU-DHL4 cells were exposed to volasertib (25 nmol/L) ± belinostat (400 nmol/L) for 24 hr after which mRNA of c-Myc was extracted and quantified as described in methods. (p < 0.05, significantly less than values for single-agent treatment). C. c-Myc shRNA (shc-Myc clone1 and clone2) and scrambled-sequence control shRNA (shCont) SU-DHL4 cells were generated and the cells were treated with volasertib (25 nmol/L) for 48 hr, after which the percentage of dead cells was determined by 7-AAD (right panel), (p < 0.05 versus control). D. shc-Myc and shCont SU-DHL4 cells were treated with volasertib for 24 hr, after which Western blot analysis was performed to monitor c-PARP, cleaved caspase-3, and γH2A.X expression.